Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced"* gastric cancer"** into a more structured format: --- ### Abstract #### Introduction This study explores the efficacy and safety of combining ceralasertib (AZD6738) with durvalumab in advanced gastric cancer patients. #### Methods - **Design**: Open-label, single-center, non-randomized, phase II clinical trial. - **Treatment**: Patients received ceralasertib (240 mg twice daily, days 15-28) with durvalumab (1500 mg, day 1 every 4 weeks). - **Endpoints**: Primary endpoint was overall response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. #### Results - **Participants**: 53 patients enrolled. - **ORR**: 22.6%. - **DCR**: 58.1%. - **PFS**: Median of 3.0 months. - **OS**: Median of 6.7 months. - **Safety**: Adverse events were manageable with dose modifications. #### Biomarker Analysis - **Findings**: Subgroup with loss of ATM expression and high HRD showed longer PFS. - **Immune Response**: Upregulation of innate immune response and activation of intratumoral lymphocytes in responders. #### Conclusion The combination of ceralasertib and durvalumab demonstrated clinical activity and manageable safety in advanced gastric cancer, particularly benefiting patients with specific biomarker profiles